Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-2)

NCT03630952 is registered in ClinicalTrials.gov with Chengdu Kanghong Biotech Co., Ltd. as lead sponsor.

NCT NCT03630952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03630952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-2)
Lead sponsor
Chengdu Kanghong Biotech Co., Ltd.
Phase
Phase 3
Overall status
Terminated
Start date
December 21, 2018
Completion date
May 19, 2021
Enrollment
1,157 (actual)
Sites
154

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration